MX2021009690A - Anticuerpo anti-bag2 y metodos de tratamiento del cancer. - Google Patents

Anticuerpo anti-bag2 y metodos de tratamiento del cancer.

Info

Publication number
MX2021009690A
MX2021009690A MX2021009690A MX2021009690A MX2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A
Authority
MX
Mexico
Prior art keywords
antibody
treating cancer
bag2
methods
fragment
Prior art date
Application number
MX2021009690A
Other languages
English (en)
Inventor
Seong Jin Kim
Dong Woo Kang
Original Assignee
Medpacto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190016359A external-priority patent/KR102241558B1/ko
Priority claimed from KR1020190016347A external-priority patent/KR102172541B1/ko
Application filed by Medpacto Inc filed Critical Medpacto Inc
Publication of MX2021009690A publication Critical patent/MX2021009690A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente solicitud se describe un anticuerpo o fragmento de unión a antígeno de este que se une con especificidad a un polipéptido BAG2 o fragmento de este, y un método de tratamiento del cáncer de este.
MX2021009690A 2019-02-12 2020-02-12 Anticuerpo anti-bag2 y metodos de tratamiento del cancer. MX2021009690A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020190016359A KR102241558B1 (ko) 2019-02-12 2019-02-12 Bag2 폴리펩티드 또는 이의 단편에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
KR1020190016347A KR102172541B1 (ko) 2019-02-12 2019-02-12 Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법
PCT/IB2020/051136 WO2020165794A1 (en) 2019-02-12 2020-02-12 Anti-bag2 antibody and methods of treating cancer

Publications (1)

Publication Number Publication Date
MX2021009690A true MX2021009690A (es) 2021-10-01

Family

ID=72044199

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009690A MX2021009690A (es) 2019-02-12 2020-02-12 Anticuerpo anti-bag2 y metodos de tratamiento del cancer.

Country Status (10)

Country Link
US (2) US20230183324A1 (es)
EP (2) EP3938788A4 (es)
JP (2) JP2022525843A (es)
CN (2) CN114269779A (es)
AU (1) AU2020222326A1 (es)
BR (1) BR112021015940A2 (es)
CA (1) CA3129748A1 (es)
MX (1) MX2021009690A (es)
SG (1) SG11202108140SA (es)
WO (2) WO2020165797A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
AU2007350901A1 (en) * 2007-04-05 2008-10-16 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
CN101999002A (zh) * 2008-02-04 2011-03-30 彼帕科学公司 诊断和治疗parp-介导的疾病的方法
WO2010065944A1 (en) * 2008-12-05 2010-06-10 Serametrix Autoantibody detection systems and methods
KR102039624B1 (ko) * 2017-03-03 2019-11-01 재단법인 차세대융합기술연구원 BAG2 및 Cathepsin B 상호결합 억제 물질 스크리닝 방법
KR102230314B1 (ko) * 2017-10-24 2021-03-22 주식회사 메드팩토 혈액으로부터 암을 진단하는 방법

Also Published As

Publication number Publication date
EP3938788A4 (en) 2023-01-04
EP3924382A4 (en) 2023-01-04
US20230194534A1 (en) 2023-06-22
CN114269779A (zh) 2022-04-01
BR112021015940A2 (pt) 2021-10-05
US20230183324A1 (en) 2023-06-15
EP3924382A1 (en) 2021-12-22
CN114761803A (zh) 2022-07-15
SG11202108140SA (en) 2021-08-30
JP2022521706A (ja) 2022-04-12
AU2020222326A1 (en) 2021-08-19
WO2020165797A1 (en) 2020-08-20
EP3938788A1 (en) 2022-01-19
JP2022525843A (ja) 2022-05-20
CA3129748A1 (en) 2020-08-20
WO2020165794A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
PH12017500229A1 (en) Combination therapies with anti cd40 antibodies
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
JOP20180021A1 (ar) الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
EA202190088A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
MX2022007676A (es) Anticuerpos caninizados biespecificos para tratar dermatitis atopica.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
MX2022001260A (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
MX2021012962A (es) Anticuerpo monoclonal que se une especificamente a gitr.
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
ZA202205288B (en) Humanized antibody and method for using the same
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation